AUS
NZ
UK
CA
USA
IND
Highlights
- First commercial sales recorded for geneType products.
- Strategic growth targeted in enterprise and global markets.
- Anticipation builds for upcoming ColoSTAT® revenue streams.
Rhythm Biosciences Ltd (ASX:RHY) has achieved a significant milestone by recording its first commercial sales of geneType products, marking a pivotal moment in the company's recent endeavors to revamp its commercial strategies. This development follows the acquisition and integration of the Genetype suite, which has been instrumental in bolstering Rhythm’s product offerings.
Since taking charge of Genetype in February 2025, Rhythm has not only handled the initial backlog of patient cases but has also started generating new sales. This progress is a testament to the successful restoration of Genetype’s commercial operations, spearheaded by a rejuvenated team dedicated to leveraging the acquired assets.
The company's future outlook is robust, with expectations of increasing commercial B2B sales throughout the year. The strategy focuses on penetrating enterprise market segments and expanding geographically, positioning Rhythm to capitalize on broader market opportunities.
Dr. David Atkins, CEO & Managing Director of Rhythm, expressed satisfaction with the company’s trajectory, stating, "It is most pleasing to have crossed this threshold, with Rhythm from here on being able to record commercial sales revenues. Although non-material, at present, we are confident that the suite of products will support commercial revenue growth over ensuing periods." Dr. Atkins credited the dedication and hard work of both the Rhythm and ongoing Genetype teams for their rapid re-establishment of commercial activities.
Looking ahead, Rhythm Biosciences is poised for further growth with its geneType™ product portfolio. Moreover, the company is eagerly anticipating the addition of commercial revenues from its ColoSTAT® product in the next financial year. ColoSTAT® represents another strategic product that could significantly impact Rhythm's commercial success and market presence.
The recording of these first sales not only symbolizes a fresh commercial beginning for the acquired geneType products but also strengthens Rhythm Biosciences' position as a forward-moving entity in the biotech industry. As Rhythm continues to expand its product portfolio and explore new market avenues, the industry watches with keen interest for its next phases of growth and innovation.
